Sellas Life Sciences Group Inc Share Price Today: Live Updates & Key Insights

Sellas Life Sciences Group Inc share price today is $4.86, up -8.46%. The stock opened at $5.55 against the previous close of $5.2, with an intraday high of $5.55 and low of $4.75.

Sellas Life Sciences Group Inc Share Price Chart

Sellas Life Sciences Group Inc

us-stock
To Invest in {{usstockname}}
us-stock

Sellas Life Sciences Group Inc Share Price Performance

$4.86 -0.0846(-8.46%) SLS at 23 Mar 2026 03:15 PM Biotechnology
Lowest Today 4.75
Highest Today 5.55
Today’s Open 5.55
Prev. Close 5.2
52 Week High 6.14
52 Week Low 0.95
Day’s Range: Low 4.75 High 5.55
52-Week Range: Low 0.95 High 6.14
1 day return -
1 Week return -10.61
1 month return +6.9
3 month return +82.16
6 month return +180.7
1 year return +285.54
3 year return +277.95
5 year return -53.62
10 year return -

Sellas Life Sciences Group Inc Institutional Holdings

Vanguard Group Inc 5.94

BlackRock Inc 3.99

Vanguard Total Stock Mkt Idx Inv 2.81

Geode Capital Management, LLC 2.16

iShares Russell 2000 ETF 2.15

Vanguard Institutional Extnd Mkt Idx Tr 1.08

Millennium Management LLC 0.97

State Street Corp 0.96

Marshall Wace Asset Management Ltd 0.94

Fidelity Small Cap Index 0.86

Two Sigma Investments LLC 0.76

Morgan Stanley - Brokerage Accounts 0.74

iShares Russell 2000 Growth ETF 0.72

Nuveen, LLC 0.72

Fidelity Extended Market Index 0.53

Northern Trust Corp 0.51

State St Russell Sm/Mid Cp® Indx SL Cl I 0.47

Vanguard Russell 2000 ETF 0.41

Dagco Inc 0.41

Vanguard US Momentum Factor ETF 0.36

Everhart Financial Group, Inc. 0.33

State St Russell Sm Cap® Indx SL Cl I 0.29

Charles Schwab Investment Management Inc 0.29

Nuveen Equity Index R6 0.27

Blackrock Extended Mkt Fund CF 0.26

iShares Core S&P Total US Stock Mkt ETF 0.25

Susquehanna International Group, LLP 0.25

GSA Capital Partners LLP 0.24

iShares Micro-Cap ETF 0.23

Extended Equity Market Fund K 0.22

Opus Capital Group LLC 0.22

Schwab Small Cap Index 0.22

NT R2000 Index Fund - NL 0.19

Fidelity Total Market Index 0.19

NT R2000 Index Fund - DC - NL - 3 0.15

iShares Russell 2000 Small-Cap Idx Instl 0.15

Bank of New York Mellon Corp 0.14

Barclays PLC 0.13

Mariner Wealth Advisors LLC 0.11

Rhumbline Advisers 0.09

Sellas Life Sciences Group Inc Market Status

Strong Buy: 2

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Sellas Life Sciences Group Inc Fundamentals

Market Cap 854.59 M

PB Ratio 20.519

PE Ratio 0.0

Enterprise Value 889.87 M

Total Assets 78.35 M

Volume 29521856

Sellas Life Sciences Group Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:1000000 1.0M, FY21:7600000 7.6M, FY20:1900 0.0M, FY19:0 0.0M

Annual Profit FY23:0 0.0M, FY22:900000 0.9M, FY21:7400000 7.4M, FY20:1900 0.0M, FY19:null 0.0M

Annual Net worth FY23:-38325000 -38.3M, FY22:-40652000 -40.7M, FY21:-20699000 -20.7M, FY20:-16757000 -16.8M, FY19:-19292000 -19.3M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-6791000 -6.8M, Q2/2025:-6601000 -6.6M, Q1/2025:-5813000 -5.8M, Q3/2024:-7108000 -7.1M, Q2/2024:-7470000 -7.5M

About Sellas Life Sciences Group Inc & investment objective

Company Information SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Organisation Biotechnology

Employees 13

Industry Biotechnology

CEO Dr. Angelos M. Stergiou M.D., ScD h.c.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Sellas Life Sciences Group Inc FAQs

What is the share price of Sellas Life Sciences Group Inc today?

The current share price of Sellas Life Sciences Group Inc is $4.86.

Can I buy Sellas Life Sciences Group Inc shares in India?

Yes, Indian investors can buy Sellas Life Sciences Group Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Sellas Life Sciences Group Inc shares in India?

You can easily invest in Sellas Life Sciences Group Inc shares from India by:

Can I buy fractional shares of Sellas Life Sciences Group Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Sellas Life Sciences Group Inc?

Sellas Life Sciences Group Inc has a market cap of $854.59 M.

In which sector does Sellas Life Sciences Group Inc belong?

Sellas Life Sciences Group Inc operates in the Biotechnology sector.

What documents are required to invest in Sellas Life Sciences Group Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Sellas Life Sciences Group Inc?

The PE ratio of Sellas Life Sciences Group Inc is N/A and the PB ratio is 20.52.